;PMID: 2498299
;source_file_1892.mrg
;Release 0.9 of PennBioIE
;Funded by NSF ITR EIA-0205448

;0)section:[e:0..41] = [t:0..41]
;1)sentence:[e:47..199] = [t:47..199]
;2)section:[e:203..231] = [t:203..231]
;3)section:[e:235..341] = [t:235..341]
;4)sentence:[e:345..524] = [t:345..524]
;5)sentence:[e:525..705] = [t:525..705]
;6)sentence:[e:706..877] = [t:706..877]
;7)sentence:[e:878..1087] = [t:878..1087]
;8)sentence:[e:1088..1363] = [t:1088..1363]
;9)sentence:[e:1364..1485] = [t:1364..1485]
;10)sentence:[e:1486..1667] = [t:1486..1667]
;11)section:[e:1671..1715] = [t:1671..1715]

;section 0 Span:0..41
;J Biochem (Tokyo). 1989 Feb;105(2):234-8.
(SEC
  (FRAG (NNP:[0..1] J) (NNP:[2..9] Biochem) (NN:[10..11] -LRB-)
        (NN:[11..16] Tokyo) (NN:[16..17] -RRB-) (.:[17..18] .)
        (CD:[19..23] 1989) (NNP:[24..31] Feb;105) (-LRB-:[31..32] -LRB-)
        (CD:[32..33] 2) (-RRB-:[33..34] -RRB-) (::[34..35] :) (CD:[35..38] 234)
        (::[38..39] -) (CD:[39..41] 8.)))

;sentence 1 Span:47..199
;Purification and properties of cytochrome P-450 generally acting as a
;catalyst  on benzo[a]pyrene hydroxylation from liver microsomes of untreated
;rats.
;[78..94]:cyp450:"cytochrome P-450"
;[117..125]:cyp450:"catalyst"
;[130..144]:substance:"benzo[a]pyrene"
(SENT
  (NP-HLN
    (NP (NN:[47..59] Purification) (CC:[60..63] and) (NNS:[64..74] properties))
    (PP (IN:[75..77] of)
      (NP
        (NP
          (NP (NN:[78..88] cytochrome) (NN:[89..94] P-450))
          (VP
            (ADVP (RB:[95..104] generally))
            (VBG:[105..111] acting)
            (PP-MNR (IN:[112..114] as)
              (NP
                (NP (DT:[115..116] a) (NN:[117..125] catalyst))
                (PP (IN:[127..129] on)
                  (NP (NN:[130..144] benzo-LSB-a-RSB-pyrene)
                      (NN:[145..158] hydroxylation)))))))
        (PP (IN:[159..163] from)
          (NP
            (NP (NN:[164..169] liver) (NNS:[170..180] microsomes))
            (PP (IN:[181..183] of)
              (NP (JJ:[184..193] untreated) (NNS:[194..198] rats)))))))
    (.:[198..199] .)))

;section 2 Span:203..231
;Ohgiya N, Yokota H, Yuasa A.
(SEC
  (FRAG (NNP:[203..209] Ohgiya) (NNP:[210..211] N) (,:[211..212] ,)
        (NNP:[213..219] Yokota) (NNP:[220..222] H,) (NNP:[223..228] Yuasa)
        (NNP:[229..230] A) (.:[230..231] .)))

;section 3 Span:235..341
;Department of Veterinary Biochemistry, School of Veterinary Medicine, Rakuno 
;Gakuen University, Hokkaido.
(SEC
  (FRAG (NNP:[235..245] Department) (IN:[246..248] of)
        (NNP:[249..259] Veterinary) (NNP:[260..272] Biochemistry)
        (,:[272..273] ,) (NNP:[274..280] School) (IN:[281..283] of)
        (NNP:[284..294] Veterinary) (NNP:[295..303] Medicine) (,:[303..304] ,)
        (NNP:[305..311] Rakuno) (NNP:[313..319] Gakuen)
        (NNP:[320..330] University) (,:[330..331] ,) (NNP:[332..340] Hokkaido)
        (.:[340..341] .)))

;sentence 4 Span:345..524
;A form of cytochrome P-450 generally catalyzing benzo[a]pyrene (B[a]P) 
;hydroxylation was purified from liver microsomes of untreated rats on the
;basis  of the catalytic activity.
;[355..371]:cyp450:"cytochrome P-450"
;[393..407]:substance:"benzo[a]pyrene"
;[409..414]:substance:"B[a]P"
(SENT
  (S
    (NP-SBJ-1
      (NP (DT:[345..346] A) (NN:[347..351] form))
      (PP (IN:[352..354] of)
        (NP
          (NP (NN:[355..365] cytochrome) (NN:[366..371] P-450))
          (VP
            (ADVP (RB:[372..381] generally))
            (VBG:[382..392] catalyzing)
            (NP
              (NML
                (NML (NN:[393..407] benzo-LSB-a-RSB-pyrene))
                (NML (-LRB-:[408..409] -LRB-) (NN:[409..414] B-LSB-a-RSB-P)
                     (-RRB-:[414..415] -RRB-)))
              (NN:[417..430] hydroxylation))))))
    (VP (VBD:[431..434] was)
      (VP (VBN:[435..443] purified)
        (NP-1 (-NONE-:[443..443] *))
        (PP (IN:[444..448] from)
          (NP
            (NP (NN:[449..454] liver) (NNS:[455..465] microsomes))
            (PP (IN:[466..468] of)
              (NP (JJ:[469..478] untreated) (NNS:[479..483] rats)))))
        (PP (IN:[484..486] on)
          (NP
            (NP (DT:[487..490] the) (NN:[491..496] basis))
            (PP (IN:[498..500] of)
              (NP (DT:[501..504] the) (JJ:[505..514] catalytic)
                  (NN:[515..523] activity)))))))
    (.:[523..524] .)))

;sentence 5 Span:525..705
;The purification procedures consisted of cholate  solubilization and
;chromatography in 3 steps, on DEAE-Toyopearl (at room  temperature),
;hydroxylapatite, and CM-Toyopearl columns.
;[566..573]:substance:"cholate"
;[624..638]:substance:"DEAE-Toyopearl"
;[663..678]:substance:"hydroxylapatite"
;[684..696]:substance:"CM-Toyopearl"
(SENT
  (S
    (NP-SBJ (DT:[525..528] The) (NN:[529..541] purification)
            (NNS:[542..552] procedures))
    (VP (VBD:[553..562] consisted)
      (PP-CLR (IN:[563..565] of)
        (NP
          (NP
            (NP (NN:[566..573] cholate) (NN:[575..589] solubilization))
            (CC:[590..593] and)
            (NP
              (NP (NN:[594..608] chromatography))
              (PP (IN:[609..611] in)
                (NP (CD:[612..613] 3) (NNS:[614..619] steps)))))
          (,:[619..620] ,)
          (PP (IN:[621..623] on)
            (NP
              (NP (NN:[624..638] DEAE-Toyopearl)
                (PRN (-LRB-:[639..640] -LRB-)
                  (PP (IN:[640..642] at)
                    (NP (NN:[643..647] room) (NN:[649..660] temperature)))
                  (-RRB-:[660..661] -RRB-))
                (NML-1 (-NONE-:[661..661] *P*)))
              (,:[661..662] ,)
              (NP (NN:[663..678] hydroxylapatite)
                (NML-1 (-NONE-:[678..678] *P*)))
              (,:[678..679] ,) (CC:[680..683] and)
              (NP (NN:[684..696] CM-Toyopearl)
                (NML-1 (NNS:[697..704] columns))))))))
    (.:[704..705] .)))

;sentence 6 Span:706..877
;Cytochrome P-450  purified in this way (named P-450/B[a]P) was homogeneous on
;SDS-polyacrylamide  gel electrophoresis, and the molecular weight was
;estimated to be 51,000.
;[706..722]:cyp450:"Cytochrome P-450"
;[752..757]:cyp450:"P-450"
;[758..763]:substance:"B[a]P"
;[870..876]:quantitative-value:"51,000"
(SENT
  (S
    (S
      (NP-SBJ
        (NP (NN:[706..716] Cytochrome) (NN:[717..722] P-450))
        (VP (VBN:[724..732] purified)
          (NP (-NONE-:[732..732] *))
          (PP (IN:[733..735] in)
            (NP (DT:[736..740] this) (NN:[741..744] way))))
        (PRN (-LRB-:[745..746] -LRB-)
          (VP (VBN:[746..751] named)
            (NP (NN:[752..757] P-450) (SYM:[757..758] /)
                (NN:[758..763] B-LSB-a-RSB-P)))
          (-RRB-:[763..764] -RRB-)))
      (VP (VBD:[765..768] was)
        (ADJP-PRD (JJ:[769..780] homogeneous))
        (PP-LOC (IN:[781..783] on)
          (NP
            (NML (NN:[784..802] SDS-polyacrylamide) (NN:[804..807] gel))
            (NN:[808..823] electrophoresis)))))
    (,:[823..824] ,) (CC:[825..828] and)
    (S
      (NP-SBJ-1 (DT:[829..832] the) (JJ:[833..842] molecular)
                (NN:[843..849] weight))
      (VP (VBD:[850..853] was)
        (VP (VBN:[854..863] estimated)
          (S
            (NP-SBJ-1 (-NONE-:[863..863] *))
            (VP (TO:[864..866] to)
              (VP (VB:[867..869] be)
                (NP-PRD (CD:[870..876] 51,000))))))))
    (.:[876..877] .)))

;sentence 7 Span:878..1087
;The  absorption spectra of the oxidized form of P-450/B[a]P showed a Soret
;peak at  417 nm, characteristic of low-spin hemoprotein, and the Soret peak
;of the  reduced cytochrome P-450-CO complex was at 451 nm.
;[926..931]:cyp450:"P-450"
;[932..937]:substance:"B[a]P"
;[962..965]:quantitative-value:"417"
;[966..968]:quantitative-units:"nm"
;[997..1008]:substance:"hemoprotein"
;[1045..1072]:substance:"cytochrome P-450-CO complex"
;[1080..1083]:quantitative-value:"451"
;[1084..1086]:quantitative-units:"nm"
(SENT
  (S
    (S
      (NP-SBJ
        (NP (DT:[878..881] The) (NN:[883..893] absorption)
            (NNS:[894..901] spectra))
        (PP (IN:[902..904] of)
          (NP
            (NP (DT:[905..908] the) (VBN:[909..917] oxidized)
                (NN:[918..922] form))
            (PP (IN:[923..925] of)
              (NP (NN:[926..931] P-450) (SYM:[931..932] /)
                  (NN:[932..937] B-LSB-a-RSB-P))))))
      (VP (VBD:[938..944] showed)
        (NP
          (NP (DT:[945..946] a) (NNP:[947..952] Soret) (NN:[953..957] peak))
          (PP (IN:[958..960] at)
            (NP (CD:[962..965] 417) (NN:[966..968] nm))))
        (,:[968..969] ,)
        (S-ADV
          (NP-SBJ (-NONE-:[969..969] *))
          (ADJP-PRD (JJ:[970..984] characteristic)
            (PP (IN:[985..987] of)
              (NP
                (NML (JJ:[988..991] low) (HYPH:[991..992] -)
                     (NN:[992..996] spin))
                (NN:[997..1008] hemoprotein)))))))
    (,:[1008..1009] ,) (CC:[1010..1013] and)
    (S
      (NP-SBJ
        (NP (DT:[1014..1017] the) (NNP:[1018..1023] Soret)
            (NN:[1024..1028] peak))
        (PP (IN:[1029..1031] of)
          (NP (DT:[1032..1035] the) (VBN:[1037..1044] reduced)
            
            (NML
              (NML (NN:[1045..1055] cytochrome) (NN:[1056..1061] P-450))
              (HYPH:[1061..1062] -) (NN:[1062..1064] CO))
            (NN:[1065..1072] complex))))
      (VP (VBD:[1073..1076] was)
        (PP-LOC-PRD (IN:[1077..1079] at)
          (NP (CD:[1080..1083] 451) (NN:[1084..1086] nm)))))
    (.:[1086..1087] .)))

;sentence 8 Span:1088..1363
;Immunochemical analysis of  P-450/B[a]P indicated that P-450/B[a]P is
;immunologically distinct from P-450b  (a major phenobarbital-inducible form
;of P-450) and P-450c (a major  3-methylcholanthrene-inducible form of P-450,
;which highly catalyzes the  hydroxylation of B[a]P).
;[1116..1121]:cyp450:"P-450"
;[1122..1127]:substance:"B[a]P"
;[1143..1148]:cyp450:"P-450"
;[1149..1154]:substance:"B[a]P"
;[1188..1194]:cyp450:"P-450b"
;[1205..1218]:substance:"phenobarbital"
;[1237..1242]:cyp450:"P-450"
;[1248..1254]:cyp450:"P-450c"
;[1265..1285]:substance:"3-methylcholanthrene"
;[1304..1309]:cyp450:"P-450"
;[1356..1361]:substance:"B[a]P"
(SENT
  (S
    (NP-SBJ
      (NP (JJ:[1088..1102] Immunochemical) (NN:[1103..1111] analysis))
      (PP (IN:[1112..1114] of)
        (NP (NN:[1116..1121] P-450) (SYM:[1121..1122] /)
            (NN:[1122..1127] B-LSB-a-RSB-P))))
    (VP (VBD:[1128..1137] indicated)
      (SBAR (IN:[1138..1142] that)
        (S
          (NP-SBJ (NN:[1143..1148] P-450) (SYM:[1148..1149] /)
                  (NN:[1149..1154] B-LSB-a-RSB-P))
          (VP (VBZ:[1155..1157] is)
            (ADJP-PRD (RB:[1158..1173] immunologically)
                      (JJ:[1174..1182] distinct)
              (PP (IN:[1183..1187] from)
                (NP
                  (NP (NN:[1188..1194] P-450b)
                    (PRN (-LRB-:[1196..1197] -LRB-)
                      (NP
                        (NP (DT:[1197..1198] a) (JJ:[1199..1204] major)
                          (ADJP (NN:[1205..1218] phenobarbital)
                                (HYPH:[1218..1219] -)
                                (JJ:[1219..1228] inducible))
                          (NN:[1229..1233] form))
                        (PP (IN:[1234..1236] of)
                          (NP (NN:[1237..1242] P-450))))
                      (-RRB-:[1242..1243] -RRB-)))
                  (CC:[1244..1247] and)
                  (NP (NN:[1248..1254] P-450c)
                    (PRN (-LRB-:[1255..1256] -LRB-)
                      (NP
                        (NP
                          (NP (DT:[1256..1257] a) (JJ:[1258..1263] major)
                            (ADJP (NN:[1265..1285] 3-methylcholanthrene)
                                  (HYPH:[1285..1286] -)
                                  (JJ:[1286..1295] inducible))
                            (NN:[1296..1300] form))
                          (PP (IN:[1301..1303] of)
                            (NP (NN:[1304..1309] P-450))))
                        (,:[1309..1310] ,)
                        (SBAR
                          (WHNP-1 (WDT:[1311..1316] which))
                          (S
                            (NP-SBJ-1 (-NONE-:[1316..1316] *T*))
                            (ADVP (RB:[1317..1323] highly))
                            (VP (VBZ:[1324..1333] catalyzes)
                              (NP
                                (NP (DT:[1334..1337] the)
                                    (NN:[1339..1352] hydroxylation))
                                (PP (IN:[1353..1355] of)
                                  (NP (NN:[1356..1361] B-LSB-a-RSB-P))))))))
                      (-RRB-:[1361..1362] -RRB-))))))))))
    (.:[1362..1363] .)))

;sentence 9 Span:1364..1485
;B[a]P hydroxylase activity in liver microsomes of  untreated rats was
;inhibited to about 20% by the P-450/B[a]P antibody.
;[1364..1381]:substance:"B[a]P hydroxylase"
;[1453..1456]:quantitative-value:"20%"
;[1464..1484]:substance:"P-450/B[a]P antibody"
(SENT
  (S
    (NP-SBJ-1
      (NP
         (NN:[1364..1369] B-LSB-a-RSB-P) (NN:[1370..1381] hydroxylase)
        (NN:[1382..1390] activity))
      (PP-LOC (IN:[1391..1393] in)
        (NP
          (NP (NN:[1394..1399] liver) (NNS:[1400..1410] microsomes))
          (PP (IN:[1411..1413] of)
            (NP (JJ:[1415..1424] untreated) (NNS:[1425..1429] rats))))))
    (VP (VBD:[1430..1433] was)
      (VP (VBN:[1434..1443] inhibited)
        (NP-1 (-NONE-:[1443..1443] *))
        (PP (TO:[1444..1446] to)
          (NP-EXT
            (QP (RB:[1447..1452] about) (CD:[1453..1455] 20))
            (NN:[1455..1456] %)))
        (PP (IN:[1457..1459] by)
          (NP-LGS (DT:[1460..1463] the)
            
            (NML (NN:[1464..1469] P-450) (SYM:[1469..1470] /)
                 (NN:[1470..1475] B-LSB-a-RSB-P))
            (NN:[1476..1484] antibody)))))
    (.:[1484..1485] .)))

;sentence 10 Span:1486..1667
;These  results demonstrate that P-450/B[a]P is a different form of P-450 from
;P-450b  and P-450c, and generally catalyzes B[a]P hydroxylation in liver
;microsomes of  untreated rats.
;[1518..1523]:cyp450:"P-450"
;[1524..1529]:substance:"B[a]P"
;[1553..1558]:cyp450:"P-450"
;[1564..1570]:cyp450:"P-450b"
;[1576..1582]:cyp450:"P-450c"
;[1608..1613]:substance:"B[a]P"
(SENT
  (S
    (NP-SBJ (DT:[1486..1491] These) (NNS:[1493..1500] results))
    (VP (VBP:[1501..1512] demonstrate)
      (SBAR (IN:[1513..1517] that)
        (S
          (NP-SBJ (NN:[1518..1523] P-450) (SYM:[1523..1524] /)
                  (NN:[1524..1529] B-LSB-a-RSB-P))
          (VP
            (VP (VBZ:[1530..1532] is)
              (NP-PRD
                (NP (DT:[1533..1534] a) (JJ:[1535..1544] different)
                    (NN:[1545..1549] form))
                (PP (IN:[1550..1552] of)
                  (NP
                    (NP (NN:[1553..1558] P-450))
                    (PP (IN:[1559..1563] from)
                      (NP (NN:[1564..1570] P-450b) (CC:[1572..1575] and)
                          (NN:[1576..1582] P-450c)))))))
            (,:[1582..1583] ,) (CC:[1584..1587] and)
            (VP
              (ADVP (RB:[1588..1597] generally))
              (VBZ:[1598..1607] catalyzes)
              (NP (NN:[1608..1613] B-LSB-a-RSB-P)
                  (NN:[1614..1627] hydroxylation))
              (PP-LOC (IN:[1628..1630] in)
                (NP
                  (NP (NN:[1631..1636] liver) (NNS:[1637..1647] microsomes))
                  (PP (IN:[1648..1650] of)
                    (NP (JJ:[1652..1661] untreated) (NNS:[1662..1666] rats))))))))))
    (.:[1666..1667] .)))

;section 11 Span:1671..1715
;PMID: 2498299 [PubMed - indexed for MEDLINE]
(SEC
  (FRAG (NNP:[1671..1675] PMID) (::[1675..1676] :) (CD:[1677..1684] 2498299)
        (NN:[1685..1686] -LSB-) (NNP:[1686..1692] PubMed) (::[1693..1694] -)
        (NN:[1695..1702] indexed) (IN:[1703..1706] for)
        (NNP:[1707..1715] MEDLINE-RSB-)))
